<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442021000100030</article-id>
<article-id pub-id-type="doi">10.24875/rmn.20000018</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Role of disease-modifying oral drugs in multiple sclerosis: A systematic review with meta-analysis]]></article-title>
<article-title xml:lang="es"><![CDATA[Papel de los fármacos orales modificadores de la enfermedad en la esclerosis múltiple: una revisión sistemática con metanálisis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Ruiz]]></surname>
<given-names><![CDATA[Minerva]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guzmán-Vázquez]]></surname>
<given-names><![CDATA[Silvia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Álvarez]]></surname>
<given-names><![CDATA[Osvaldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Buendía-López]]></surname>
<given-names><![CDATA[Yareli O.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soto-Molina]]></surname>
<given-names><![CDATA[Herman]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General de México Department of Neurology ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,HS Estudios Farmacoeconómicos  ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2021</year>
</pub-date>
<volume>22</volume>
<numero>1</numero>
<fpage>30</fpage>
<lpage>39</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442021000100030&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442021000100030&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442021000100030&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The purpose of the study was to evaluate the efficacy and safety of cladribine tablets compared with all oral therapies used in patients with relapsing-remitting multiple sclerosis (RRMS). A systematic review of the literature was conducted to identify published clinical trials about RRMS and a network meta-analysis was performed to determine the efficacy and safety of available treatments. We identified seven relevant studies, which were selected based on three criteria that allowed us to construct comparisons of efficacy and safety. Regarding the annualized relapse rate (ARR), there were no significant differences with respect to the decrease of this between cladribine tablets, dimethyl fumarate and fingolimod; although teriflunomide and cladribine tablets showed a significant difference. In relation to the mean number of gadolinium-enhanced T1 lesions, dimethyl fumarate showed a lower number of lesions (&#8722;0.85 [&#8722;1.21; &#8722;0.48]), as did cladribine tablets versus placebo. No statistically significant differences were identified between cladribine tablets and fingolimod (&#8722;0.08 [&#8722;0.35; 0.19]) and cladribine versus teriflunomide (&#8722;0.28 [&#8722;0.64; 0.08]). While comparing adverse events that caused discontinuation, cladribine tablets showed an adequate safety profile, which was quantitatively similar to the compared drugs. Cladribine tablets demonstrated efficacy in terms of decrease of ARR and gadolinium-enhanced T1 lesions; although there is no significant difference between cladribine tablets, fingolimod and teriflunomide, the ARR is a stronger measure of efficacy compared to the number of T1 lesions made in contrast with long-term RRMS. Cladribine also demonstrated an adequate safety and tolerability profile promoting therapeutic adherence.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El propósito del estudio fue evaluar la eficacia y seguridad de las tabletas de cladribina en comparación con todas las terapias orales utilizadas en pacientes con EMRR. Se realizó una revisión sistemática de la literatura para identificar ensayos clínicos publicados sobre EMRR y un metanálisis de red para determinar la eficacia y seguridad de los tratamientos disponibles. Identificamos 7 estudios relevantes, que se seleccionaron en base a 3 criterios que nos permitieron construir comparaciones de eficacia y seguridad. En cuanto a la tasa de recaída anualizada, no hubo diferencias significativas con respecto a la disminución de ésta entre las tabletas de cladribina, dimetilfumarato y fingolimod; aunque las tabletas de teriflunomida y cladribina mostraron una diferencia significativa. En relación con el número medio de lesiones T1 potenciadas con gadolinio, dimetilfumarato mostró un menor número de lesiones (&#8722;0.85 [&#8722;1.21; &#8722;0.48]), al igual que las tabletas de cladribina frente a placebo. No se identificaron diferencias estadísticamente significativas entre las tabletas de cladribina y fingolimod (&#8722;0.08 [&#8722;0.35; 0.19]) y cladribina vs teriflunomida (&#8722;0.28 [&#8722;0.64; 0.08]). Al comparar los eventos adversos que causaron la suspensión, las tabletas de cladribina mostraron un perfil de seguridad adecuado, que fue cuantitativamente similar a los medicamentos comparados. Las tabletas de cladribina demostraron eficacia en términos de disminución de la tasa de recaída anualizada y lesiones T1 potenciadas con gadolinio; Aunque no existe una diferencia significativa entre las tabletas de cladribina, fingolimod y teriflunomida, la tasa de recaída anualizada es una medida más fuerte de eficacia en comparación con el número de lesiones T1 realizadas en contraste con la EMRR a largo plazo. Cladribina también demostró un perfil adecuado de seguridad y tolerabilidad que promueve la adherencia terapéutica.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Relapsing-remitting multiple sclerosis]]></kwd>
<kwd lng="en"><![CDATA[Cladribine tablets]]></kwd>
<kwd lng="en"><![CDATA[Disease-modifying treatments]]></kwd>
<kwd lng="es"><![CDATA[Esclerosis múltiple recurrente-remitente]]></kwd>
<kwd lng="es"><![CDATA[Tabletas de cladribina]]></kwd>
<kwd lng="es"><![CDATA[Tratamientos modificadores de la enfermedad]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noseworthy]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Lucchinetti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Weinshenker]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple sclerosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2000</year>
<volume>343</volume>
<page-range>938-52</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lublin]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
<name>
<surname><![CDATA[Reingold]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Cutter]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Sørensen]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Defining the clinical course of multiple sclerosis:the 2013 revisions]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2014</year>
<volume>83</volume>
<page-range>278-86</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ziemssen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Symptom management in patients with multiple sclerosis]]></article-title>
<source><![CDATA[J Neurol Sci]]></source>
<year>2011</year>
<volume>311</volume>
<page-range>S48-52</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Duron]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Macias]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple sclerosis care in Latin America]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2014</year>
<volume>82</volume>
<page-range>1660-1</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giovannoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Southam]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Waubant]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis:tolerability and adherence]]></article-title>
<source><![CDATA[Mult Sclerosis]]></source>
<year>2012</year>
<volume>18</volume>
<page-range>932-46</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[World Health Organization. Adherence to Long-term Therapies]]></article-title>
<source><![CDATA[Evidence for Action (WHO/MN/0.30.1)]]></source>
<year>2003</year>
<page-range>211</page-range><publisher-loc><![CDATA[Washington, DC ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruce]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hancock]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Objective adherence monitoring in multiple sclerosis:initial validation and association with self-report]]></article-title>
<source><![CDATA[Mult Sclerosis]]></source>
<year>2010</year>
<volume>16</volume>
<page-range>112-20</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beutler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cladribine (2-chlorodeoxyadenosine)]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1992</year>
<volume>340</volume>
<page-range>952-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brousil]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schlein]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cladribine:an investigational immunomodulatory agent for multiple sclerosis]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2006</year>
<volume>40</volume>
<page-range>1814-21</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Science Medicines Health]]></article-title>
<source><![CDATA[Summary of Product Characteristics:mavenclad (cladribine)]]></source>
<year>2017</year>
<page-range>1-41</page-range><publisher-loc><![CDATA[Netherlands ]]></publisher-loc>
<publisher-name><![CDATA[European Medicines Agency Science Medicines Health]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alva]]></surname>
<given-names><![CDATA[CIE]]></given-names>
</name>
</person-group>
<source><![CDATA[El Significado Psicológico de la Experiencia del Parto Con el Apoyo Continuo de Doula:un Estudio Comparativo Con Redes Semánticas Naturales]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Colima ]]></publisher-loc>
<publisher-name><![CDATA[Tesis de Maestría Universidad de Colima]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giovannoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cladribine to treat relapsing forms of multiple sclerosis]]></article-title>
<source><![CDATA[Neurotherapeutics]]></source>
<year>2017</year>
<volume>14</volume>
<page-range>874-87</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siddiqui]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Khurana]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Budhia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hettle]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Harty]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2018</year>
<volume>34</volume>
<page-range>1361-71</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papadopoulos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mitsikostas]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral disease-modifying treatments for relapsing multiple sclerosis:a likelihood to achieve no evidence of disease activity or harm analysis]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2018</year>
<volume>32</volume>
<page-range>1069-78</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kappos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Radue]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[O'Connor]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Polman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hohlfeld]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Calabresi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>362</volume>
<page-range>387-401</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giovannoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Comi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rammohan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rieckmann]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Soelberg Sørensen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>362</volume>
<page-range>416-26</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calabresi]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Radue]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Goodin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jeffery]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rammohan]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Reder]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II):a double-blind, randomised, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>545-56</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Connor]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wolinsky]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Confavreux]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Comi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kappos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Olsson]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized trial of oral teriflunomide for relapsing multiple sclerosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>365</volume>
<page-range>1293-303</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Confavreux]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[O'Connor]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Comi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Olsson]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER):a randomised, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>247-56</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gold]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kappos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Bar-Or]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Giovannoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Selmaj]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>367</volume>
<page-range>1098-107</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchinson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Havrdova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>367</volume>
<page-range>1087-97</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faissner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gold]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of the newer multiple sclerosis drugs approved since 2010]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2018</year>
<volume>32</volume>
<page-range>269-87</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
